

Drug Monograph

Drug/Drug **Altreno™ (tretinoin) Lotion / Topical Retinoids**

Class:

Prepared for: MO HealthNet

Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Altreno™ is available as a 0.05% lotion in a 45-gram tube.
Manufacturer:	Manufactured for: Dow Pharmaceutical Sciences, a division of Valeant Pharmaceuticals North America LLC., Bridgewater, NJ 08807
Indications:	Altreno™ is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
Costs:	\$114.75 per 45-gram tube of Altreno™ lotion. Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input checked="" type="checkbox"/> PDL Edit
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input checked="" type="checkbox"/> Under Solicitation <input type="checkbox"/> Appropriate Indications <input type="checkbox"/> No PA Required

Prepared By: Tyler Woods PharmD

Date: January 7, 2019